{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:45:49Z","timestamp":1648615549559},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/bmt.2017.65","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T14:21:30Z","timestamp":1491229290000},"page":"1068-1070","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"52","author":[{"given":"S","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Koganesawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Isoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"BFbmt201765_CR1","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005\u20133020.","journal-title":"Blood"},{"key":"BFbmt201765_CR2","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578\u20131582.","journal-title":"Blood"},{"key":"BFbmt201765_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomized controlled trial. Lancet 2012; 379: 1301\u20131309.","journal-title":"Lancet"},{"key":"BFbmt201765_CR4","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/S0021-9258(18)83672-9","volume":"264","author":"K Suzuki","year":"1989","unstructured":"Suzuki K, Hayashi T, Nishioka J, Kosaka Y, Zushi M, Honda G et al. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 1989; 264: 4872\u20134876.","journal-title":"J Biol Chem"},{"key":"BFbmt201765_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized double-blind clinical trial. J Thromb Haemost 2007; 5: 31\u201341.","journal-title":"J Thromb Haemost"},{"key":"BFbmt201765_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1172\/JCI22782","volume":"115","author":"K Abeyama","year":"2005","unstructured":"Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267\u20131274.","journal-title":"J Clin Invest"},{"key":"BFbmt201765_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2009.217","volume":"45","author":"T Ikezoe","year":"2010","unstructured":"Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A . Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783\u2013785.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201765_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ajh.22137","volume":"86","author":"C Ohwada","year":"2011","unstructured":"Ohwada C, Takeuchi M, Kawaguchi T, Tsukamoto S, Sakai S, Takeda Y et al. Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome\/hepatic veno-occlusive disease after bone marrow transplantation. Am J Hematol 2011; 86: 886\u2013888.","journal-title":"Am J Hematol"},{"key":"BFbmt201765_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BFbmt201765_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51: 906\u2013912.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201765_CR11","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","volume":"2","author":"GB McDonald","year":"2002","unstructured":"McDonald GB . Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma 2002; 2: S35\u2013S39.","journal-title":"Clin Lymphoma"},{"key":"BFbmt201765_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12185-014-1616-9","volume":"100","author":"H Nakayama","year":"2014","unstructured":"Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A et al. Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. Int J Hematol 2014; 100: 171\u2013179.","journal-title":"Int J Hematol"},{"key":"BFbmt201765_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al. BCSH\/BSBMT guideline: diagnose and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163: 444\u2013457.","journal-title":"Br J Haematol"},{"key":"BFbmt201765_CR14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","volume":"103","author":"B Versluys","year":"2004","unstructured":"Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968.","journal-title":"Blood"},{"key":"BFbmt201765_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1160\/TH10-12-0802","volume":"105","author":"S Nomura","year":"2011","unstructured":"Nomura S, Ozasa R, Nakanishi T, Fujita S, Miyaji M, Mori S et al. Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation? Thromb Haemost 2011; 105: 1118\u20131120.","journal-title":"Thromb Haemost"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201765","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:04:45Z","timestamp":1648065885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFbmt201765"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.65","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"3 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}